Traci Bratton

Traci Bratton

| This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact:
(205) 934-2040
traci@uab.edu 
The greatest excitement at the moment surrounds the new class of checkpoint inhibitors, including PD-1 and CTLA-4 inhibitors. "Your body has a natural response of putting the brakes on the immune system," says Arend. "These drugs take those brakes off."
Immunotherapy has revolutionized treatment options in oncology, neurology, and many infectious diseases and now there is fresh hope that the same method could be used to treat or even functionally cure HIV, according to new research.
A key mechanism describing how internal biochemical clock signals get turned into changes in external electrical firing activity, have been identified.
While an antibody named VRC01 was safe and well-tolerated in the studies, it was only briefly effective at suppressing the AIDS virus in 24 patients taken off standard anti-viral drugs.
Sarah Parcak, an archeologist based at the University of Alabama at Birmingham, was recently awarded the 2016 American Ingenuity Award from Smithsonian Magazine.
Everyone’s looking for a little peace — and students have found it in the UAB College of Arts and Sciences, a growing hub for the study of peaceful societies, human rights, nonviolent conflict resolution, and related topics. Discover useful tips for defusing friction with family and neighbors, and learn more about the practical lessons of peace.
David Kimberlin, M.D., has received a prestigious award and $100,000 grant from Ronald McDonald House Charities for accomplishments in pediatric medicine and infectious disease control.
Testing the ability of early exposure to hinder later reactions to allergens, University of Alabama at Birmingham researchers used another common pest, mice, to gauge resistance to cockroach-induced asthma.
Luis Cruz Azaceta: War and Other Disasters is on view at Abroms-Engel Institute for the Visual Arts in Birmingham, Alabama, through December 17, 2016.
The study combined all phase-three randomized controlled clinical trials comparing different novel oral blood thinners, left atrial appendage closure devices, known as WATCHMAN devices, and Coumadin (warfarin) for stroke prevention in patients with non-valvular atrial fibrillation.
Back to Top